logo

Onconova Therapeutics, Inc (ONTX)



Trade ONTX now with
  Date
  Headline
1/23/2020 8:46:40 AM Onconova Therapeutics Regains Rights To Rigosertib In Greater China
12/17/2019 7:59:57 AM Onconova, Pint Pharma Announce Brazilian Health Authority Approval For Beginning INSPIRE Trial
12/6/2019 7:37:00 AM Inceptua Medicines Access And Onconova Announce Pre-approval Access Collaboration For Rigosertib Outside The US
12/6/2019 7:34:37 AM Onconova Therapeutics And Inceptua Medicines Access Enter Collaboration
5/13/2019 7:38:52 AM Onconova Therapeutics Announces License Agreement With HanX Biopharma To Develop Rigosertib In Greater China
3/26/2019 7:42:10 AM ONCONOVA THERAPEUTICS FY Loss Per Share $4.99 Vs Loss $40.15 Last Year
1/15/2019 5:20:06 PM Onconova Therapeutics Promotes Steven Fruchtman To CEO
1/2/2019 7:34:13 AM Onconova Submits Special Protocol Assessment To FDA For Phase 3 Trial Of Oral Rigosertib In Combination With Azacitidine
12/3/2018 7:47:58 AM Onconova Therapeutics Presents Results From Phase 2 Trial Of Oral Rigosertib In Combination With Azacitidine
11/13/2018 7:13:24 AM Onconova Therapeutics Q3 Loss Per Share $0.94 Vs Loss $10.60 Last Year
11/5/2018 8:36:33 AM Onconova Announces Four Presentations From Rigosertib Clinical Trials In Myelodysplastic Syndromes
10/17/2018 8:36:37 AM Onconova Therapeutics Reports Issuance Of New U.S. Patent For Rigosertib
8/21/2018 8:36:29 AM Onconova Says Pint Pharma GmbH Will Assist In Expanding Access To Clinical Trials Studying Rigosertib